Medicare Part D Coverage Restrictions and Patient Cost-Sharing for Opioids Commonly Used for Cancer Pain, 2015-2021

Yuhua Bao*, Hao Zhang, Daniel M. Hartung, Lisa R. Witkin, Judith A. Paice

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

5 Scopus citations

Abstract

PURPOSE:Nation-wide rapid declines in prescription opioid dispensing gave rise to concerns regarding restricted access to effective pain management for patients with cancer-related pain. One important mechanism for such restrictions could be through more restrictive insurance coverage for opioids. This study aims to assess recent changes in Medicare Part D formulary designs for opioids commonly used for cancer-related pain.METHODS:We used data from the 2015-2021 Medicare Prescription Drug Plan (PDP) Formulary Files to assess formulary changes for six opioid-dose combinations commonly used for cancer-related pain. We estimated % of PDPs adopting prior authorization, quantity limits (and limits adopted), and a higher cost-sharing tier for each opioid-dose combination. We further estimated median and mean out-of-pocket (OOP) costs across all PDPs for a 30-day supply of the drug. Trends in proportions were tested using the Cochrane-Armitage test; trends in continuous measures were tested using the Jonckheere-Terpstra test.RESULTS:Proportion of PDPs adopting prior authorization increased from close to 0% to about 50% for two long-acting opioids (P <.001). Distribution of quantity limits across PDPs shifted over time to being more restrictive for all opioids considered (P <.001). For four of the six opioids, the proportion of PDPs adopting tier 3 or above increased from below or about 50% to well over 70% (P <.001). For the same four opioids, median OOP costs doubled to quadrupled (P <.001).CONCLUSION:Medicare PDP coverage has become increasingly restrictive for opioids commonly used for cancer-related pain, with multifold increases in patient OOP costs over the past 7 years. These changes pose concerns for patients with cancer needing opioid therapies for pain control and call for strategies to effectively exempt cancer-related pain from insurance and pharmacy rules intended to apply to opioids for noncancer chronic pain.

Original languageEnglish (US)
Pages (from-to)E1574-E1586
JournalJCO Oncology Practice
Volume18
Issue number10
DOIs
StatePublished - Oct 1 2022

Funding

Y.B. and H.Z. were supported by a grant from Arnold Ventures and a grant from the National Institute on Drug Abuse (P30DA040500).

ASJC Scopus subject areas

  • Health Policy
  • Oncology(nursing)
  • Oncology

Fingerprint

Dive into the research topics of 'Medicare Part D Coverage Restrictions and Patient Cost-Sharing for Opioids Commonly Used for Cancer Pain, 2015-2021'. Together they form a unique fingerprint.

Cite this